Senate schedules hearing for FDA nominee as Novo teams with Anthropic on AI drug development
read at raps ↗RegulatoryNeutral
The Senate has announced a hearing to consider the nominee for the next FDA commissioner, signaling a forthcoming review of the agency's leadership.
In parallel, biotech firm Novo has entered a partnership with AI company Anthropic to explore artificial‑intelligence approaches for drug discovery and development.
The dual announcements highlight both regulatory scrutiny and emerging technology collaborations that could shape the pharmaceutical landscape in the coming months.
source
This writeup was produced by pharmadog from original reporting by raps.
Original headline: “Recon: Senate hearing set for FDA nominee; Novo partners with Anthropic for AI drug development”
read at raps ↗
comments(0)
5-min edit window · permanent after that